CLL/SLL

ASCO 2016 Education Session – Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?

During ASCO 2016, an education session took place on Saturday June 4, 08:00–09:15am, titled ‘Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?’ This session began by everybody being welcomed and the speakers being introduced by the Chair, Dr John M Pagel, Associate Professor and Associate Member in the Clinical Research Division at the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance in Seattle, Washington. This was then followed by three presentations and a panel question and answer session. All presentations in this session followed the ‘Value’ track.

The first presentation was given by Professor Michael J Hallek who is Professor of Medicine, Director, and Chair of the Department of Internal Medicine at the University of Cologne, Germany. The presentation was called ‘Chronic Lymphocytic Leukemia: Pathogenesis, Prognostic Factors and Role of Chemoimmunotherapy in 2016’.

Targeted Therapy in Chronic Lymphocytic Leukemia: Where Are We Now?’ was the second presentation given during this education session. Jennifer R Brown, MD, PhD, Associate Professor of Medicine at Harvard Medical School and Director of the CLL Center at the Dana-Farber Cancer Institute was the speaker.

The last presentation was given by the session’s Chair, Dr John M Pagel and was titled ‘CLL 2016: Select Unanswered Questions’. This presentation is associated with an ASCO 2016 Educational Book of the same title, authored by Brown, Hallek and Pagel.